Guiding the future of clinical care and clinical research in Birt-Hogg-Dubé

Michel Alchoueiry,W. Clark Lambert,Elizabeth P. Henske
DOI: https://doi.org/10.1038/s41431-024-01696-7
2024-09-29
European Journal of Human Genetics
Abstract:Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder caused by germline loss-of-function mutations in the Folliculin gene ( FLCN ). The Folliculin (FLCN) protein forms a complex with the folliculin interacting proteins 1 and 2 (FNIP1, FNIP2) and functions in multiple signaling and metabolic pathways such as AMPK-mediated energy sensing and mTORC1-dependent cell proliferation. BHD is associated with benign skin tumors (~90% penetrance by age 70 years), renal cell carcinoma (RCC, penetrance of 15–30%), and cystic lung disease (24–48% penetrance). The lung cysts can rupture spontaneously, leading to pneumothorax (median age at first pneumothorax is 34 years with a range from 7 to 78 yrs) [1]. It is estimated that 10% of individuals with pneumothorax have an underlying genetic syndrome with BHD having the highest prevalence. The RCC in BHD can have distinctive features, including chromophobe-oncocytic morphology [2]. Geilswijk et al. [3] have developed an international consensus clinical practice guidelines for the diagnosis, surveillance, and management of individuals with BHD. These guidelines are much-needed, especially since recent data from a population-based health care setting indicates an incidence of loss-of-function FLCN mutation, about 60-fold higher than prior estimates. Accurate diagnosis is often challenging: the skin manifestations can be subtle and difficult to diagnose, and age-dependent penetrance might not be evident until later adulthood, after a pneumothorax or renal tumor has developed.
genetics & heredity,biochemistry & molecular biology
What problem does this paper attempt to address?